Delcath Systems (NASDAQ:DCTH) Now Covered by Analysts at

Equities research analysts at assumed coverage on shares of Delcath Systems (NASDAQ:DCTHGet Rating) in a research report issued on Sunday. The firm set a “sell” rating on the stock.

DCTH has been the topic of a number of other reports. BTIG Research cut their price target on shares of Delcath Systems from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Friday, June 24th. HC Wainwright lowered their price objective on Delcath Systems from $25.00 to $19.00 and set a “buy” rating for the company in a research report on Wednesday, August 10th.

Delcath Systems Stock Down 1.3 %

Shares of NASDAQ:DCTH opened at $3.86 on Friday. The company has a debt-to-equity ratio of 2.55, a current ratio of 1.57 and a quick ratio of 1.40. The firm has a market capitalization of $33.20 million, a PE ratio of -1.01 and a beta of 0.87. The firm’s 50-day moving average is $4.20 and its two-hundred day moving average is $4.90. Delcath Systems has a 1 year low of $3.49 and a 1 year high of $11.95.

Delcath Systems (NASDAQ:DCTHGet Rating) last issued its quarterly earnings results on Monday, August 8th. The company reported ($1.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.30). The business had revenue of $0.80 million for the quarter, compared to analysts’ expectations of $1.26 million. Delcath Systems had a negative return on equity of 465.64% and a negative net margin of 797.19%. Analysts predict that Delcath Systems will post -3.86 EPS for the current year.

Insider Activity

In other news, CEO Gerard J. Michel acquired 62,814 shares of the firm’s stock in a transaction dated Wednesday, July 20th. The stock was acquired at an average cost of $3.98 per share, with a total value of $249,999.72. Following the completion of the acquisition, the chief executive officer now owns 125,864 shares of the company’s stock, valued at $500,938.72. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 16.76% of the company’s stock.

Institutional Investors Weigh In On Delcath Systems

Several large investors have recently modified their holdings of DCTH. Millennium Management LLC purchased a new stake in shares of Delcath Systems during the second quarter worth approximately $40,000. Dimensional Fund Advisors LP purchased a new position in Delcath Systems in the first quarter worth $75,000. CI Investments Inc. purchased a new position in Delcath Systems in the first quarter worth $559,000. Cibc World Market Inc. raised its position in Delcath Systems by 4.0% in the first quarter. Cibc World Market Inc. now owns 88,751 shares of the company’s stock worth $568,000 after acquiring an additional 3,432 shares in the last quarter. Finally, CIBC World Markets Inc. purchased a new position in Delcath Systems in the fourth quarter worth $661,000. Hedge funds and other institutional investors own 26.18% of the company’s stock.

About Delcath Systems

(Get Rating)

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

See Also

Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with's FREE daily email newsletter.